MediWound
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 100
- Market Cap
- $186.6M
- Website
- http://www.mediwound.com
- Introduction
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
MediWound Announces Phase II Head-to-Head Study Evaluating
MediWound to initiate a controlled, multicenter Phase II clinical study evaluating EscharEx® against collagenase ointment for treating venous leg ulcers (VLUs) in 2025, supporting its Biologics License Application (BLA) and commercialization strategy. The study will involve 45 patients across multiple sites in the U.S. and Europe, with strategic R&D collaborations with Solventum and Mölnlycke to enhance trial consistency and patient outcomes.
MediWound Ltd. Announces Phase II Head-To-Head Study Evaluating EscharEx
MediWound to initiate a multicenter Phase II study in 2025 evaluating EscharEx® against collagenase for venous leg ulcers (VLUs), running concurrently with a Phase III trial. The randomized study will enroll 45 patients across the U.S. and Europe, assessing key safety and efficacy endpoints. Strategic R&D collaborations with Solventum and Mölnlycke Health Care will support the trial.
MediWound advances EscharEx in Phase II VLU study
MediWound Ltd. initiates a Phase II study in 2025 to evaluate EscharEx for venous leg ulcers, comparing it to collagenase ointment. The trial includes 45 patients across the U.S. and Europe, focusing on safety and efficacy. Strategic R&D collaborations with Solventum and Mölnlycke support the trial. EscharEx, enriched with bromelain, has shown safety and efficacy in previous trials. MediWound's CEO expects the study to validate EscharEx's effectiveness. The company also expands NexoBrid's use in pediatric patients and reports strong financial performance.
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs Collagenase Ointment for Venous Leg Ulcers
MediWound to initiate a controlled, multicenter Phase II clinical study evaluating EscharEx® against collagenase ointment for the treatment of venous leg ulcers (VLUs) in 2025, supporting the Biologics License Application (BLA) for EscharEx and strengthening the commercialization strategy. The study will enroll 45 patients across multiple sites in the U.S. and Europe, with strategic R&D collaborations formed with Solventum and Mölnlycke to enhance trial consistency and patient outcomes.
© Copyright 2025. All Rights Reserved by MedPath